REPL- Replimune Group, Inc.

Insider activity in REPL over the last quarter tilts toward buying: insiders added a net 2,657,216 shares worth roughly $32.0M.

Classified under Biotechnology (Health Care sector), REPL's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
10%	Baker Bros. Advisors LP	2.61M	$31.48M	-
Dir	Astley-Sparke Philip	1.36M	-	-
CEO	Patel Sushil	708.2K	$9.18M	-
Other	Xynos Konstantinos	224.2K	$2.91M	-
CFO	Hill Emily Luisa	215.9K	$3.08M	-

Buys and sells only

10 filings

Date	Insider	Role	Type	Shares	Price	Value	Chg%
Aug 17, 2026	Hill Emily Luisa62	Chief Financial Officer	Sell	9,256	$14.28	$132,175.68	-4.1%
Aug 10, 2026	Schwendenman Andrew	Chief Accounting Officer	Sell	7,632	$12.97	$98,987.04	-7.1%
Aug 10, 2026	Xynos Konstantinos53	Chief Medical Officer	Sell	11,447	$12.97	$148,467.59	-4.9%
Aug 10, 2026	Patel Sushil66	Chief Executive Officer	Sell	39,341	$12.97	$510,252.77	-5.3%
Aug 10, 2026	Hill Emily Luisa62	Chief Financial Officer	Sell	11,448	$12.97	$148,480.56	-4.8%
Jun 1, 2026	Sarchi Christopher53	Chief Commercial Officer	Sell	12,000	$9.24	$110,880.00	-6.2%
May 18, 2026	Xynos Konstantinos53	Chief Medical Officer	Sell	14,023	$5.08	$71,236.84	-5.6%
May 18, 2026	Sarchi Christopher53	Chief Commercial Officer	Sell	8,626	$5.08	$43,820.08	-4.3%
May 18, 2026	Schwendenman Andrew	Chief Accounting Officer	Sell	7,894	$5.08	$40,101.52	-6.9%
May 18, 2026	Patel Sushil66	Chief Executive Officer	Sell	37,324	$5.08	$189,605.92	-4.8%